febuxostat治疗痛风的效果？

(Febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has a high utilization rate. Food and antacids have no significant effect on its absorption. Unlike allopurinol, its structure is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes in purine or pyrimidine metabolism. This means that febuxostat is less likely to be affected by other factors and has a stable effect.

The starting dose of febuxostat is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh classes A and B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh class C) should use febuxostat with caution.

Pediatric Use: The safety and effectiveness of this product in treating patients under 18 years of age have not been established.

Elderly patients: No dosage adjustment is required for elderly patients. According to foreign literature reports, in clinical studies of febuxostat, people aged 65 and over accounted for 16% of the total number of subjects, and people aged 75 and over accounted for 4%. Comparing subjects of different age groups, there is no clinically significant difference in effectiveness and safety, but it cannot be ruled out that some elderly patients are more sensitive to this product. After multiple oral administrations of febuxostat to elderly subjects (65 years and above), Cmax and AUC24 were similar to those of young subjects (18 to 40 years old).

How effective is febuxostat in treating gout?

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of this product was significantly lower than before treatment. According to the dose, each group decreased by an average of 3 7%, 44% and 59%, while patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial, and the incidence of adverse reactions was similar to that in the placebo group, and most of these adverse reactions were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.